Loading patent…
OwnerDonglai Wu, Xiangang Kong +12inventors
InventorsDonglai Wu, Xiangang Kong, Qingwen Meng, Yonggang Liu, Yuntao Guan, Xunnan Yin, Mouping Wang, Changwen Li, Ming Liao, Chao-an Xin, Jinding Chen, Changchun Tu, Hua Xuan, Yedong Yu
Estimating the term…
The present invention is directed towards the use of the masked palm civet Paguma larvata (“civet”) as an animal model system for SARS, and is based on the novel demonstration of the present invention that civets may be infected with exogenous coronavirus, and that such infection produces SARS-like symptoms in these infected animals. The present invention is directed to a civet model system for the study of the infection, replication, and clinical effects of exogenously introduced human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof, and to the development of vaccines (or other methods of prevention) or treatment of infection or transmission to other civets or humans of these human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof.
A civet infected with an exogenous coronavirus or variant or derivative of said exogenous coronavirus.
A method for producing coronavirus in a civet, comprising infecting a civet with an exogenous coronavirus or variant or derivative of said exogenous coronavirus.
A method for assaying the development of SARS-like symptoms in a civet, comprising:
A method for assaying the effect of a putative coronaviral protection agent on the development of SARS-like symptoms in a civet, comprising:
A method for assaying the effect of a putative coronaviral vaccine agent on the development of SARS-like symptoms in a civet, comprising:
A method for preventing or reducing SARS-like symptoms in a civet, comprising inoculating a civet with a coronaviral protection agent or coronaviral vaccine agent.
Dependencies are inferred from the claim text.